Last Updated : May 4, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name Sort descending | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Tysabri | Natalizumab | Multiple Sclerosis, relapsing-remitting | List with clinical criteria and/or conditions | Complete | ||
| Tysabri | Natalizumab | Multiple Sclerosis, relapsing-remitting | Do not list | Complete | ||
| Bystolic | Nebivolol | Hypertension | Do not list at the submitted price | Complete | ||
| Atriance | Nelarabine | Cancelled | ||||
| Atriance | nelarabine | T-cell acute lymphoblastic leukemia | Reimburse with clinical criteria and/or conditions | Complete | ||
| Nerlynx | Neratinib | ERBB2-positive breast cancer | Do not reimburse | Complete | ||
| Akynzeo | netupitant / palonosetron | Nausea and vomiting (chemotherapy induced) prevention | Reimburse with clinical criteria and/or conditions | Complete | ||
| Advicor | Niacin/lovastatin | Hypercholesterolemia and mixed dyslipidemia | List | Complete | ||
| Ofev | nintedanib | chronic fibrosing interstitial lung diseases | Reimburse with clinical criteria and/or conditions | Complete | ||
| Ofev | Nintedanib | Idiopathic pulmonary fibrosis | List with clinical criteria and/or conditions | Complete |
Last Updated : May 4, 2024